SEC Form 4 · accession 0001179110-15-007529
ALBANY MOLECULAR RESEARCH INC · AMRI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven R Hagen
Officer — SVP Manufacturing & Pharmaceut
Period of report
May 8, 2015
Accepted (ET)
May 11, 2015 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001065087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2015 | M | 7,000 | $8.90 | A | 38,200 | D | |
| Common Stock | May 8, 2015 | S | 7,000 | $19.35 | D | 31,200 | D | |
| Common Stock | May 8, 2015 | M | 7,500 | $11.21 | A | 38,700 | D | |
| Common Stock | May 8, 2015 | S | 7,500 | $19.20 | D | 31,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $8.90 | May 8, 2015 | M | 7,000 | A | — | Mar 8, 2020 | Common Stock | 7,000 | 0 | D |
| Option to Purchase Common StockF2 | $11.21 | May 8, 2015 | M | 7,500 | A | — | Mar 17, 2018 | Common Stock | 7,500 | 0 | D |
Explanation of responses
- F1Option grant was fully exercisable March 8, 2015.
- F2Option grant was fully exercisable March 17, 2013.